Department of Neuroscience, University of Virginia School of Medicine, Charlottesville, VA, USA.
Center for Brain Immunology and Glia, University of Virginia School of Medicine, Charlottesville, VA, USA.
J Neuroinflammation. 2023 Oct 21;20(1):242. doi: 10.1186/s12974-023-02924-5.
Microglia, the primary immune cells of the central nervous system (CNS), are derived from the yolk sac and populate the brain during development. Once microglia migrate to the CNS, they are self-renewing and require CSF1R signaling for their maintenance. Pexidartinib (PLX3397, PLX), a small molecule inhibitor of the CSF1R, has been shown to effectively deplete microglia since microglial maintenance is CSF1R-dependent. There have, however, been several conflicting reports that have shown the potential off-target effects of PLX on peripheral immune cells particularly those of lymphoid origin. Given this controversy in the use of the PLX family of drugs, it has become important to ascertain to what extent PLX affects the peripheral immune profile in lymphoid (spleen, and bone marrow) and non-lymphoid (kidney, lungs, and heart) organs. PLX3397 chow treatment at 660 mg/kg for 7 days significantly reduced CD45 macrophages, CX3CR1-GFP cells, CD11bCD45 cells, and P2RY12 expression in the brain. However, there were minimal effects on peripheral immune cells from both lymphoid and non-lymphoid organs except in the heart where there was a significant decrease in CD3 cells, inflammatory and patrolling monocytes, and CD11bLy6G neutrophils. We then stimulated the immune system with 1 mg/kg of LPS which resulted in a significant reduction in the number of innate immune cells. In this context, PLX did not alter the cytokine profile in the serum and the brain of naïve mice but did so in the LPS-stimulated group resulting in a significant reduction in TNFα, IL-1α, IFN-γ and IL-1β. Furthermore, PLX did not alter locomotor activity in the open field test suggesting that microglia do not contribute to LPS-induced sickness behavior. Our results provide an assessment of immune cell populations with PLX3397 treatment on brain, lymphoid and non-lymphoid organs without and during LPS treatment that can serve as a resource for understanding consequences of such approaches.
小胶质细胞是中枢神经系统 (CNS) 的主要免疫细胞,来源于卵黄囊,并在发育过程中迁移到大脑。一旦小胶质细胞迁移到 CNS,它们就会自我更新,并依赖 CSF1R 信号来维持。Pexidartinib(PLX3397,PLX)是 CSF1R 的小分子抑制剂,已被证明可以有效地消耗小胶质细胞,因为小胶质细胞的维持依赖于 CSF1R。然而,有几项相互矛盾的报告表明,PLX 对周围免疫细胞(特别是淋巴来源的免疫细胞)可能存在脱靶效应。鉴于 PLX 类药物的使用存在这种争议,确定 PLX 在多大程度上影响淋巴(脾脏和骨髓)和非淋巴(肾脏、肺和心脏)器官中的外周免疫谱变得尤为重要。PLX3397 饲料处理 7 天,660mg/kg 显著减少了大脑中的 CD45 巨噬细胞、CX3CR1-GFP 细胞、CD11bCD45 细胞和 P2RY12 表达。然而,除了心脏,对来自淋巴和非淋巴器官的外周免疫细胞几乎没有影响,心脏中 CD3 细胞、炎性和巡逻单核细胞以及 CD11bLy6G 中性粒细胞显著减少。然后,我们用 1mg/kg 的 LPS 刺激免疫系统,导致固有免疫细胞数量显著减少。在这种情况下,PLX 没有改变未刺激 LPS 的小鼠血清和大脑中的细胞因子谱,但在刺激 LPS 的组中却改变了细胞因子谱,导致 TNFα、IL-1α、IFN-γ 和 IL-1β 显著减少。此外,PLX 没有改变旷场试验中的运动活动,表明小胶质细胞不会导致 LPS 诱导的疾病行为。我们的研究结果提供了在没有和有 LPS 处理的情况下,PLX3397 处理对大脑、淋巴和非淋巴器官中的免疫细胞群的评估,这可以作为理解此类方法后果的资源。